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INTRODUCTION
Hepatocellular carcinoma (HCC) ranks fifth in cancer incidence and third in cancer related deaths world wide [1] . The majority of patients diagnosed with HCC are not candidates for surgical resection or liver transplant and require different liver directed therapies for disease management [2, 3] . One of these recognized treatments for HCC is hepatic radioembolization with Yttrium90 (Y90) microspheres, which demonstrated good results in controlling liver disease with a relatively safe toxicity profile [4] . Fluorodeoxyglucose positron emission tomography (FDGPET) has proven to provide prognostic information in multiple solid tumors [58] but is not routinely used in the work up for HCC due to a low sensitivity (50%70%) [911] . Multiple studies have shown a cor relation between standardized uptake value (SUV) of HCC on FDGPET scans and outcomes following different systemic and locoregional treatments [1222] . In this study, we assessed the prognostic value of pretreatment FDGPET/CT scans in HCC patients undergoing liver radioembolization with Y90 microspheres.
MATERIALS AND METHODS
Institutional review board (IRB) approval was obtained to retrospectively review charts for patients with HCC treated with Y90 glass microsphere radioembolization at our institution between August 2009 and October 2013. At our institution, upon diagnosis of HCC, patients are evaluated by a multidisciplinary hepa tology team with referral to radiation oncology and interventional radiology if the decision was made to administer Y90 glass microspheres for disease management. From a wellmaintained database for all patients treated with radioembolization for HCC we were able to retrospectively identify patients who had PET/CT for various reasons prior to diagnosis and treatment.
All PET/CT images were reviewed at our institution by one of three nuclear radiologists with at least 10year experience. FDG avidity was defined as maximal standardized uptake value (SUVmax) ≥ 3 of the liver lesion and/or higher than background activity in the surrounding normal liver tissue.
As part of this study, various reasons to obtain PET/CT were reviewed and collected. All other scans were also reviewed by our radiologist to characterize disease. BarcelonaClinic Liver Cancer (BCLC) staging and classification system [23] incorporating Okuda [24] staging system was used to classify patients. Factors in staging system were also recorded separately to be included in the analysis including: performance status, ChildPugh class, liver function, portal invasion, presence of extrahepatic disease, and tumor burden in the liver.
Patient evaluation and treatment
Pretreatment evaluation included: clinical assessment, laboratory work up with a comprehensive metabolic panel to evaluate hepatic and renal function, alpha fetoprotein (AFP) level, and multiphasic CT scan or MRI scan of the liver. HCC diagnosis was made clinically and radiographically with confirmatory biopsy for further confirmation when felt necessary. Prior to radioembolization, an angiographic evalua tion of hepatic vasculature was performed followed by hepatic injection of Tc99m macroaggregated albumin (MAA) to determine the lung shunt fraction. The volume of liver to be treated was measured based on crosssectional imaging. This was then used to calculate the radiation activity based on the formula for Y90 glass microspheres {A(Gbq) = [D(Gy) × M(kg)]/50}, A is the activity, D the nominal target dose, and M the liver mass for the planned target volume (PTV) (i.e., segment, lobe, or whole liver) being treated) [25, 26] . All treatments were performed in an outpatient setting. Four patients were treated with two radioembolization treatments to separate lobes.
All patients were seen one month after treatment in the interventional radiology and radiation oncology clinic with clinical examination, complete blood count, complete metabolic panel, AFP level and multiphasic crosssectional imaging (CT scan or MRI liver protocol) to assess response to treatment and progression. Subsequent followups were done at 23 mo intervals. Timetoevent outcomes were calculated from the time of radioembolization. The time to disease progression in the treated liver lobe/segment was defined as local liver control (LLC), and the time to progression in the liver outside the treated lesion was defined as distant liver control (DLC). Progression free survival (PFS) was calculated from the time of radioembolization to the time of intrahepatic, extrahepatic progression, death, or last followup. The rate of distant metastases (DM) was calculated after excluding patients with extrahepatic disease at time of radioembolization from analysis for DM. Overall survival (OS) was calculated from the time of radioembolization to the time of death.
The primary endpoint for this study was LLC. Secondary endpoints included DLC, DM, PFS, and OS. Outcomes were calculated from the date of radioembolization with patients censored at last follow up or death. 
Statistical analysis

RESULTS
Patient and lesion characteristics
Thirtyfour patients with HCC undergoing radioem bolization procedures with pretreatment FDGPET/CT scans were identified. The reasons for obtaining PET/ CT scan were as follows: initial work up of liver mass in 23 patients (67%), history of a prior nonHCC cancer in 6 patients (18%), to rule out metastatic disease in 3 patients (9%), or due to atypical nondiagnostic findings on prior imaging in 2 (6%) patients. Eighteen patients (53%) had a PET/CT scan performed at an outside institution but were reviewed by our nuclear radiologists.
In those 34 patients, radioembolization was delivered to a total of 38 liver lobes and segments. Median age of patients was 68 years (range 4684 years), with the majority being male (74%, n = 25), and fourteen (41%) patients had no known previous cirrhotic liver on presentation. There were 20 patients (59%) with cirrhosis that was secondary to hepatitis C, hepatitis B, alcohol, and nonalcoholic steatohepatitis in 10 patients (50%), 2 patients (10%), 4 patients (20%) and 4 patients (20%), respectively. Extra hepatic disease was present in 3 (9%) patients and the majority of patients (n = 32, 94%) were not candidates for liver resection or transplant. Two patients (6%) were referred for downstaging using radioembolization prior to surgical resection. Table 1 details patient, tumor, and treatment characteristics.
Percutaneous imageguided liver lesion biopsy was performed to confirm diagnosis in 31 patients. Histopathology grade was determined in 25 patients, 18 (53%) of which had a welldifferentiated HCC, 6 moderately differentiated (18%) and one (3%) poorly differentiated HCC. Nine patients who did not undergo a biopsy or who had lesions of unknown grade were grouped together (n= 9; 26%). There were 31 patients (91%) with ChildPugh Class (CP) A and 3 patients (9%) with CP B. Portal vein thrombosis was present in 5 patients (15%). Median AFP prior to treatment was 14 ng/mL (1186000). Y90 glass microspheres were injected intraarterially to treat a median volume of 1146 cc (1912340) of the liver with a median delivered dose of 126.6 Gy (110.5478.6).
Nineteen patients (56%) were considered as having an FDGavid HCC. Figure 1 shows two patients with different FDG avidity. Female gender was the with a faster progression inside the liver with 1 year DLC rate of 44.4%, as compared to 91.7% for non FDGavid disease (P = 0.003) ( Figure 2B ). On both UVA and MVA, FDGavidity was a predictor for DLC [P = 0.03, HR = 57.7 (2.2-1496.9)], Table 3 . Significant variables on UVA include: performance status, poorly differentiated pathology, extrahepatic disease and tumor burden > 50%, but all were not statistically significant on MVA, Table 3 .
Initially, there were 3 patients with extrahepatic disease at the time of treatment. On UVA, the presence of this correlated with worse outcome in LLC, DLC, and OS (P < 0.05), but it was not included in statistical analysis for DM. Upon follow up, there were 4 patients who progressed in extrahepatic sites after radioembolization. After excluding patients with extrahepatic disease at the time of treatment from the analysis, the median for freedom from DM was not reached and freedom from DM at 1 and 2year were 96% and 54%, respectively. On UVA, FDGavid disease only factor found to be associated with HCC FDGavid disease (P = 0.047), Table 2 .
LLC, DLC, and OS outcomes
The median follow up for all patients was 12 mo (range 163 mo). The median LLC for all liver volumes treated (n = 38) was 11.3 mo. FDGavid disease was associated with shorter LLC. In comparison to non FDGavid disease, the 1year rate of LLC was 17.2% vs 61.4% (P = 0.003) with a median LLC of 5 mo vs 17 mo, respectively (Figure 2A ). On UVA, FDG avid disease, tumor burden > 50% and extrahepatic disease were associated with worse LLC and there was a trend for worse LLC for female gender and poorly differentiated HCC. However, on MVA, only FDG avidity [P = 0.002, HR = 6.3 (220)] and presence of extrahepatic disease [P < 0.001, HR = 38.9 (6.6229.2)] were associated with worse LLC Table 3 .
The median disease control in the untreated liver or DLC was 26.3 mo. FDGavid disease was associated ( Figure 3A ) and poorly differentiated tumors were associated with worse DM, but none were significant on MVA (Table 3) .
FDGavid disease was associated with shorter PFS. The 1 year PFS was higher for non FDGavid disease (43.3%) when compared to FDGavid disease (9.4%) on univariate analysis (logrank test, P = 0.015) ( Figure 3B ). On multivariate analysis, FDGavid disease was a predictor for worse PFS [P = 0.008, HR = 4 (1.411.3)] (Table 3) .
For all patients, the 1-year OS rate was 77%. There was no statistically significant difference in survival at one year between FDG-avid and non FDG-avid disease (77% vs 76.2%, P = 0.89). On UVA, other factors resulting in shorter OS were low performance status, presence of extrahepatic disease and tumor burden > 50% (all P < 0.05), with trending values for older age, presence of cirrhosis, and higher BCLC stage. The MVA analysis included component of staging system that were significant on UVA (Table 3) .
DISCUSSION
In this retrospective analysis of 34 HCC patients undergoing 38 liver radioembolizations, we found that pretreatment tumor FDGavidity correlated with worse LLC, DLC, and PFS outcomes. However, these differences in LLC and DLC with FDGavid disease did not translate into a difference in OS in our study. FDG retention in malignant cells is dependent on intracellular glucose6phosphatase enzymatic activity [27] . HCCs contain varying levels of this enzyme [28, 29] , and therefore the reported sensitivity of FDG PET/CT scans in detecting hepatocellular carcinoma ranges between 50% and 70% [911] . The low sensitivity and variation in FDG uptake are the main reasons for not routinely including FDG PET/CT imaging in the initial HCC work up. Despite their high accuracy in diagnosing HCC, CT and MRI cannot distinguish well differentiated from poorly differentiated HCC [30] . Since a large number of HCCs do not get biopsied, FDG PET may play a noninvasive role in predicting tumor biology and behavior, as the variability of FDG uptake has been linked to HCC's microvascular invasion and differentiation [3133] , and proliferative activity [34] . It was not possible to draw any conclusions regarding the relationship between FDG tumor uptake and histopathologic grade in our study since the patient population was skewed with only one patient having a poorly differentiated HCC.
Our analysis found female patients to be more likely to have FDGavid disease. In a study by Salem et al [4] , female patients with HCC treated with radioembolization were found to have shorter survival. The reason for this finding is still unknown, but might be related to the promotion of HCC in post menopausal patients due to the loss of estrogen's protective effect [35, 36] . However, unlike FDG avidity, gender was not asso ciated with worse outcomes in our MVA. Given the small number of patients and retrospective nature of our study, drawing firm conclusions regarding the impact of gender on clinical outcomes following HCC radioembolization is limited. 
A B
The role of FDGPET in the assessment of different treatment modalities for HCC has been described in several reports [1622] . Pant et al [17] assessed pre treatment FDGavidity as a prognostic index in the management of HCC in 100 patients. In their study, FDGavidity was defined as activity above the liver background, which is similar to what we used in our study. FDGavid disease was associated with a higher radiological stage, increased risk of distant metastases, invasion into the portal vein, and higher tumor grade [17] . A study by Kornberg et al [20] consisting of 91 HCC patients undergoing transplantation showed tumortobackground ratio of > 1 on pretransplant scans was associated with worse recurrence free survival of 81% vs 21% (P = 0.02). Lee et al [21] showed in 59 patients, that ratio of tumor SUVmax to liver SUVmax with cutoff value of 1.15 was the most significant predictor for tumor recurrence at 1 year with rates of 97% vs 57% (P < 0.001). Another study from Korea by Kim et al [22] showed that FDG uptake volume products was also an effective predictor for posttransplant recurrence. Lee et al [19] assessed the value of FDGPET scans in 29 patients treated with sorafenib. The max SUV was a statistically significant prognostic factor for OS and PFS. The study from Lee and colleagues used a SUVmax cut off value of 5. The group of patients with SUVmax lower than 5 had a significantly longer PFS and OS [19] . The role of FDGPET scans for patients with hepatocellular carcinoma has also been assessed in patients following transarterial chemotherapy embolization (TACE) [16, 18] . Cho et al [16] found after a mean followup of 8 months (range, 159 mo), among the 47 patients who underwent TACE, a higher ratio of tumor SUVmax to mean mediastinal SUV of ≥ 3.1
was associated with higher rates of recurrence and lower survival (94% vs 64%, P = 0.016). Kim et al [18] showed that SUVmax to mean liver SUV ratio of 1.83 was a predictor for disease progression and worse OS. In these 2 studies, different SUV ratios and cutoff values were used. The majority of PET scans evaluated in our study were performed in an outside facility, and due to the lack of standardized PET scan protocols, we opted to use a simpler way to classify FDGavidity by comparing tumor uptake to liver background. Another study by Lee et al [37] evaluated the tumorto liver uptake ratio in a total of 214 patients treated with either external radiation or TACE and they found that a ratio more than 2 correlated on MVA with worse PFS and OS. Our study is limited by its retrospective nature with a relatively small number of patients, short followup, and heterogeneous background of liver disease. It is difficult to find HCC patients that underwent an FDG-PET scan since this imaging modality is not routinely ordered due to previous reports of poor sensitivity [911] . More than half of FDGPET/CT scans were performed at an outside facility and thus there was no standardized PET scan protocol used across studies. Therefore, we
were not able to directly compare tumor SUV from different institutions. However, absolute SUV can vary significantly even within the same institution [38] and there are multiple reports on the equivalence of using qualitative SUV in relation to background in comparison to absolute SUV [39] . The selection of SUVmax of 3 might introduce bias in patient categorization, but based on previously mentioned reports, the selected value will ensure selecting patients with true active disease above normal liver background, which ranges between 1.52 [40] . This provides a minimum of tumor to Liver SUV ratio of 1.5, which correlated with outcomes in several publications [41] . Regarding a potential selection bias, there were only 2 patients in our study with atypical features for HCC on diagnostic imaging, and the majority of PET scans were performed to exclude nonHCC etiologies prior to proper diagnostic imaging. Furthermore, since most of the HCC lesions were well differentiated or were not histopathologically graded after percutaneous biopsy, this lack of histopathology information and uneven distribution, limited our ability to correlate pathological grade with clinical endpoints. As expected, the majority of patients treated with this focal therapy were BCLC stage B and C, with smaller number in stage A and only one patient with stage D (Table 1 ). The stage incorporation and analysis was weakly associated with outcome, so the multivariate analysis included significant components of this staging system that had stronger associations with outcome on UVA (i.e., ECOG Performance status, extrahepatic disease, and tumor burden) ( Table 3) . Despite these limitations, our results were in line with other studies that found a similar prognostic benefit to pre-treatment FDGPET/CT scans in patients getting treated for HCC [1622] .
In conclusion, previous studies have found a prog nostic benefit to pretreatment FDGPET/CT scans following TACE, surgery, and sorafenib treatment of HCC. Similarly, in our study, we found high FDG avidity to correlate with worse clinical outcomes of LLC, DLC, and PFS following radioembolization of HCC. As opposed to the initial reports on FDGPET that showed limited utility in the diagnosis of HCC, our study supports the growing body of evidence for the prognostic utility of pretreatment FDGPET/CT scan in the management of HCC. Pretreatment FDGPET scan may compliment staging multiphasic cross sectional imaging studies, and help determine whether there is a need for more aggressive treatment approaches. Further investigation is needed to validate our initial findings as well as the optimal method to incorporate FDGPET/CT scans in the initial work up of HCC.
COMMENTS
Background
Hepatocellular carcinoma (HCC) is the third leading cause of death from all cancers. The majority of patients with HCC present beyond eligibility criteria for surgical resection or transplant, and require local liver directed therapy.
